Progress in the delivery of nanoparticle constructs: Towards clinical translation

Current Opinion in Pharmacology

Volumn 18, Issue , 2014, Pages 120-128

  Ryan, Sinéad M ^a   Brayden, David J ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CREMOPHOR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FERUMOXSIL; FERUMOXYTOL; GEMCITABINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IBRITUMOMAB TIUXETAN; IRON OXIDE; LIPOSOME; METAL NANOPARTICLE; NANOPARTICLE; PACLITAXEL; PLACEBO; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRASTUZUMAB; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEUKEMIA; MENINGITIS; MULTIPLE MYELOMA; NANOMEDICINE; NANOTECHNOLOGY; NONHODGKIN LYMPHOMA; OSTEOARTHRITIS; OVARY CANCER; PANCREAS CANCER; SOLID TUMOR; SYSTEMATIC REVIEW; TRANSLATIONAL RESEARCH; DIAGNOSTIC USE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84908155900     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.09.019     Document Type: Review

References (36)

1. A. Babu, A.K. Templeton, A. Munshi, and R. Ramesh Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer AAPS PharmSciTech 15 2014 709 721
2. J. Key, and J.F. Leary Nanoparticles for multimodal in vivo imaging in nanomedicine Int J Nanomed 9 2014 711 726
3. W.H. Chen, X.D. Xu, H.Z. Jia, Q. Lei, G.F. Luo, S.X. Cheng, R.X. Zhuo, and X.Z. Zhang Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo Biomaterials 34 2013 8798 8807
4. G.V. Glinsky Rna-guided diagnostics and therapeutics for next-generation individualized nanomedicine J Clin Invest 123 2013 2350 2352
5. U. Nagaich Nanomedicine: revolutionary trends in drug delivery and diagnostics J Adv Pharm Technol Res 5 2014 1
6. A. Hafner, J. Lovric, G.P. Lakos, and I. Pepic Nanotherapeutics in the EU: an overview on current state and future directions Int J Nanomed 9 2014 1005 1023
7. M.L. Etheridge, S.A. Campbell, A.G. Erdman, C.L. Haynes, S.M. Wolf, and J. McCullough The big picture on nanomedicine: the state of investigational and approved nanomedicine products Nanomed Nanotechnol Biol Med 9 2013 1 14
8. R. Juliano Nanomedicine: is the wave cresting? Nat Rev Drug Discov 12 2013 171 172
9. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol Pharm 8 2011 2101 2141
10. C.L. Ventola The nanomedicine revolution: Part 3: regulatory and safety challenges P & T: Peer-reviewed J Form Manage 37 2012 631 639
11. I.P. Kaur, V. Kakkar, P.K. Deol, M. Yadav, M. Singh, and I. Sharma Issues and concerns in nanotech product development and its commercialization J Control Release 2014 10.1016/j.jconrel.2014.06.005 [Epub ahead of print]
12. D.W. Hobson Commercialization of nanotechnology Wiley Interdisciplinary Rev Nanomed Nanobiotechnol 1 2009 189 202
13. S.M. Ryan, J. McMorrow, A. Umerska, H.B. Patel, K.N. Kornerup, L. Tajber, E.P. Murphy, M. Perretti, O.I. Corrigan, and D.J. Brayden An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis J Control Release 167 2013 120 129
14. D.A. Scheinberg, C.H. Villa, F.E. Escorcia, and M.R. McDevitt Conscripts of the infinite armada: systemic cancer therapy using nanomaterials Nat Rev Clin Oncol 7 2010 266 276
15. B.W. Stewart, and C.P. Wild World cancer report 2014 IARC 2014
16. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat Rev Drug Discov 7 2008 771 782
17. J.K. Simpson, R.F. Miller, and M.F. Spittle Liposomal doxorubicin for treatment of aids-related kaposi's sarcoma Clin Oncol (R Coll Radiol) 5 1993 372 374
18. E. Miele, G.P. Spinelli, E. Miele, F. Tomao, and S. Tomao Albumin-bound formulation of paclitaxel (abraxane abi-007) in the treatment of breast cancer Int J Nanomed 4 2009 99 105
19. D.L. Stirland, J.W. Nichols, S. Miura, and Y.H. Bae Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice J Control Release 172 2013 1045 1064
20. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, and M. Harris Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703
21. M. Yokoyama Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors J Exp Clin Med 3 2011 151 158
22. S. Svenson Clinical translation of nanomedicines Curr Opin Solid State Mater Sci 16 2012 287 294
23. J.R. Beech, S.J. Shin, J.A. Smith, and K.A. Kelly Mechanisms for targeted delivery of nanoparticles in cancer Curr Pharm Design 19 2013 6560 6574
24. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O.C. Farokhzad Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv Drug Deliv Rev 66 2014 2 25
25. N. Desai Challenges in development of nanoparticle-based therapeutics AAPS J 14 2012 282 295
26. M.E. Davis The first targeted delivery of sirna in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol Pharm 6 2009 659 668
27. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered sirna via targeted nanoparticles Nature 464 2010 1067 1070
28. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, and S. Low Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci Transl Med 4 2012 128ra139
29. J. Voigt, J. Christensen, and V.P. Shastri Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae Proc Natl Acad Sci U S A 111 2014 2942 2947
30. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Nanotheranostics and image-guided drug delivery: current concepts and future directions Mol Pharm 7 2010 1899 1912
31. T. Lammers, L.Y. Rizzo, G. Storm, and F. Kiessling Personalized nanomedicine Clin Cancer Res 18 2012 4889 4894
32. J.H. Ryu, S. Lee, S. Son, S.H. Kim, J.F. Leary, K. Choi, and I.C. Kwon Theranostic nanoparticles for future personalized medicine J Control Release 190 2014 477 484
33. S. Mura, J. Nicolas, and P. Couvreur Stimuli-responsive nanocarriers for drug delivery Nat Mater 12 2013 991 1003
34. S.S. Hedgire, M. Mino-Kenudson, A. Elmi, S. Thayer, C. Fernandez-Del Castillo, and M.G. Harisinghani Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: An initial experience with histopathologic correlation Int J Nanomed 9 2014 1891 1896
35. L. Li, W. Jiang, K. Luo, H. Song, F. Lan, Y. Wu, and Z. Gu Superparamagnetic iron oxide nanoparticles as mri contrast agents for non-invasive stem cell labeling and tracking Theranostics 3 2013 595 615
36. C. Xu, and W. Zhao Nanoparticle-based monitoring of stem cell therapy Theranostics 3 2013 616 617